PMID- 30539508
OWN - NLM
STAT- MEDLINE
DCOM- 20190531
LR  - 20200511
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 995
DP  - 2018
TI  - Skin Reactions to Immune Checkpoint Inhibitors.
PG  - 117-129
LID - 10.1007/978-3-030-02505-2_5 [doi]
AB  - The novelty of immune checkpoint inhibitors has only recently led to the 
      characterization of cutaneous adverse events (AEs). This, along with the 
      substantial rate of cutaneous reactions, has left many clinicians without 
      sufficient familiarity to diagnose and treat. Pruritus and rash are among the top 
      five immune-related AEs reported in clinical trials for this class of therapy. 
      Incidence varies between 35 and 50% for cutaneous AEs among the three 
      FDA-approved drugs. Although only 2% are reported as grade 3 or 4 events, the 
      quality of life impact can be significant for these patients and is best 
      described in ipilimumab trials. 43.5% of ipilimumab patients have a cutaneous AE 
      and, at our institution, 20% of them had a dose interruption as a result. This 
      means potentially 9% of patients having dose interruption of ipilimumab because 
      of their cutaneous AEs. In the following chapter, we will review the categories 
      of these drugs, common cutaneous effects, their grading, and management options.
FAU - Patel, Anisha B
AU  - Patel AB
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA. APatel11@mdanderson.org.
FAU - Pacha, Omar
AU  - Pacha O
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Exanthema/*chemically induced
MH  - Humans
MH  - Immunotherapy/*adverse effects
MH  - Ipilimumab/*adverse effects/therapeutic use
MH  - Pruritus/*chemically induced
MH  - Quality of Life
OTO - NOTNLM
OT  - Anti-CTLA-4
OT  - Anti-PD-1
OT  - Dermatitis
OT  - Immune checkpoint inhibitors
OT  - Immunotherapy
OT  - Ipilimumab
OT  - Nivolumab
OT  - Pruritus
OT  - Rash
EDAT- 2018/12/13 06:00
MHDA- 2019/06/01 06:00
CRDT- 2018/12/13 06:00
PHST- 2018/12/13 06:00 [entrez]
PHST- 2018/12/13 06:00 [pubmed]
PHST- 2019/06/01 06:00 [medline]
AID - 10.1007/978-3-030-02505-2_5 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2018;995:117-129. doi: 10.1007/978-3-030-02505-2_5.